UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Exosomes Market DataM Intelligence forecasts robust exosome market growth fueled by AI-driven diagnostics, automated manufacturing, and str ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" ...

The research team led by Senior Researchers Yoonhee Lee from the Division of Biomedical Technology and Gyogwon Koo from the ...

Compared to the previous quarter, both analysts and management exhibited increased caution and a more defensive posture, particularly around guidance credibility and nonclinical revenue challenges.

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.

Fort Myers-based NeoGenomics reported mixed results for the second quarter. Revenue grew 10% over the year, but the net loss ...